The endocannabinoid anandamide downregulates IL-23 and IL-12 subunits in a viral model of multiple sclerosis: Evidence for a cross-talk between IL-12p70/IL-23 axis and IL-10 in microglial cells

Brain, Behavior, and Immunity

Volumn 25, Issue 4, 2011, Pages 736-749

  Correa, Fernando ^a,b   Hernangómez Herrero, Miriam ^a   Mestre, Leyre ^a   Loría, Frida ^a   Docagne, Fabian ^a,c   Guaza, Carmen ^a  

^a INSTITUTO CAJAL   (Spain)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c GIP CYCERON   (France)

Author keywords

Anandamide; Endocannabinoids; IL 10; IL 12p70; IL 23; Microglia; Multiple sclerosis; TMEV

Indexed keywords

ANANDAMIDE; CANNABINOID 2 RECEPTOR; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P70; INTERLEUKIN 17; INTERLEUKIN 23; MESSENGER RNA; METHANANDAMIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; MICROGLIA; MOLECULAR INTERACTION; MOTOR DYSFUNCTION; MOUSE; MULTIPLE SCLEROSIS; MURINE ENCEPHALOMYELITIS VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SPINAL CORD; UPREGULATION; VIRUS INFECTION;

ADAPTIVE IMMUNITY; ANALYSIS OF VARIANCE; ANIMALS; ARACHIDONIC ACIDS; CARDIOVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; ENDOCANNABINOIDS; FEMALE; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-23; INTERLEUKINS; MICE; MICROGLIA; MULTIPLE SCLEROSIS; NERVOUS SYSTEM AUTOIMMUNE DISEASE, EXPERIMENTAL; NEUROIMMUNOMODULATION; POLYUNSATURATED ALKAMIDES; PROTEIN SUBUNITS; RECEPTOR CROSS-TALK; RNA, MESSENGER; SIGNAL TRANSDUCTION; STATISTICS, NONPARAMETRIC; THEILOVIRUS;

EID: 79954937143     PISSN: 08891591     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbi.2011.01.020     Document Type: Article

References (70)

1. Aggarwal S.N., Ghilardi M.H., Xie F.J., de Sauvage A., Gurney L. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 2003, 278:1910-1914.
2. Al-Salleeh F., Petro T.M. Promoter analysis reveals critical roles for SMAD-3 and ATF-2 in expression of IL-23 p19 in macrophages. J. Immunol. 2008, 181:4523-4533.
3. Arévalo-Martín A., Vela J.M., Molina-Holgado E., Borrell J., Guaza C. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J. Neurosci. 2003, 23:2511-2516.
4. Arévalo-Martín A., García-Ovejero D., Gómez O., Rubio-Araiz A., Navarro-Galvé B., Guaza C., Molina-Holgado E., Molina-Holgado F. CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies. Br. J. Pharmacol. 2008, 153:216-225.
5. Ascherio A., Munger K.L. 99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: Epstein-Barr virus and multiple sclerosis: epidemiological evidence. Clin. Exp. Immunol. 2010, 160:120-124.
6. Baker D., Pryce G., Croxford J.L., Brown P., Pertwee R.G., Makriyannis A., Khanolkar A., Layward L., Fezza F., Bisogno T., Di Marzo V. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 2001, 15:300-302.
7. Becher B., Durell B.G., Noelle R.J. IL-23 produced by CNS-resident cells controls T cell encephalitogenicity during the effector phase of experimental autoimmune encephalomyelitis. J. Clin. Invest. 2003, 112:1186-1191.
8. Benito C., Romero J.P., Tolon R.M., Clemente D., Docagne F., Hillard C.J., Guaza C., Romero J. Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J. Neurosci. 2007, 27:2396-2402.
9. Berdyshev E.V., Schmid P.C., Krebsbach R.J., Hillard C.J., Huang C., Chen N., Dong Z., Schmid H.H. Cannabinoid-receptor-independent cell signalling by N-acylethanolamines. Biochem. J. 2001, 360:67-75.
10. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., Weiner H.L., Kuchroo V.K. Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature 2006, 441:235-238.
11. Bisogno T., Melck D., De P.L., Bobrov M.Y., Gretskaya N.M., Bezuglov V.V., Sitachitta N., Gerwick W.H., Di Marzo V. Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase. Biochem. Biophys. Res. Commun. 1998, 248:515-522.
12. Cabral G.A., Griffin-Thomas L. Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. Expert Rev. Mol. Med. 2009, 20:11-24.
13. Cabral G.A., Marciano-Cabral F. Cannabinoid receptors in microglia of the central nervous system: immune functional relevance. J. Leukoc. Biol. 2005, 78:1192-1197.
14. Cabranes A., Venderova K., de Lago E., Fezza F., Sánchez A., Mestre L., Valenti M., García-Merino A., Ramos J.A., Di Marzo V., Fernández-Ruiz J. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. Neurobiol. Dis. 2005, 20:207-217.
15. Cao S., Liu J., Chesi M., Bergsagel P.L., Ho I.C., Donnelly R.P., Ma X. Differential regulation of IL-12 and IL-10 gene expression in macrophages by the basic leucine zipper transcription factor c-Maf fibrosarcoma. J. Immunol. 2002, 169:5715-5725.
16. Centonze D., Bari M., Rossi S., Prosperetti C., Furlan R., Fezza F., De Chiara V., Battistini L., Bernardi G., Bernardini S., Martino G., Maccarrone M. The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. Brain 2007, 130:2543-2553.
17. Chen Y., Langrish C.L., McKenzie B., Joyce-Shaikh B., Stumhofer J.S., McClanahan T., Blumenschein W., Churakovsa T., Low J., Presta L., Hunter C.A., Kastelein R.A., Cua D.J. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J. Clin. Invest. 2006, 116:1317-1326.
18. Constantinescu C.S., Tani M., Ransohoff R.M., Wysocka M., Hilliard B., Fujioka T., Murphy S., Tighe P.J., Das Sarma J., Trinchieri G., Rostami A. Astrocytes as antigen presenting cells: expression of IL-12/IL-23. J. Neurochem. 2005, 95:331-340.
19. Correa F., Mestre L., Docagne F., Guaza C. Activation of cannabinoid CB2 receptor negatively regulates IL-12p40 production in murine macrophages: role of IL-10 and ERK1/2 kinase signaling. Br. J. Pharmacol. 2005, 145:441-448.
20. Correa F., Docagne F., Clemente D., Mestre L., Becker C., Guaza C. Anandamide inhibits IL-12p40 production by acting on the promoter repressor element GA-12: possible involvement of the COX-2 metabolite prostamide E(2). Biochem. J. 2008, 409:761-770.
21. Correa F., Docagne F., Mestre L., Clemente D., Hernangómez M., Loría F., Guaza C. A role for CB2 receptors in anandamide signalling pathways involved in the regulation of IL-12 and IL-23 in microglial cells. Biochem. Pharmacol. 2009, 77:86-100.
22. Correa F., Hernangómez M., Mestre L., Loría F., Spagnolo A., Docagne F., Di Marzo V., Guaza C. Anandamide enhances IL-10 production in activated microglia by targeting CB(2) receptors: roles of ERK1/2, JNK, and NF-kappaB. Glia 2010, 58:135-147.
23. Cravatt B.F., Demarest K., Patricelli M.P., Bracey M.H., Giang D.K., Martin B.R., Lichtman A.H. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. USA 2001, 98:9371-9376.
24. Croxford J.L., Miller S.D. Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55, 212. J. Clin. Invest. 2003, 111:1231-1240.
25. Cua D., Sherlock J.J., Chen Y., Murphy C.A., Joyce B., Seymour B., Lucian L., To W., Kwan S., Churakova T., Zurawski S., Wiekowski M., Lira S.A., Gorman D., Kastelein R.A., Sedgwick J.D. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003, 421:744-748.
26. D'Andrea A., Aste-Amezaga M., Valiante N.M., Ma X., Kubin M., Trinchieri G. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J. Exp. Med. 1993, 178:1041-1048.
27. Docagne F., Mestre L., Loría F., Hernangómez M., Correa F., Guaza C. Therapeutic potential of CB2 targeting in multiple sclerosis. Expert Opin. Ther. Targets 2008, 12:185-195.
28. Dong C., Davis R.J., Flavell R.A. MAP kinases in the immune response. Annu. Rev. Immunol. 2002, 20:55-72.
29. Eljaschewitsch E., Witting A., Mawrin C., Lee T., Schmidt P.M., Wolf S., Hoertnagl H., Raine C.S., Schneider-Stock R., Nitsch R., Ullrich O. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 2006, 49:67-79.
30. Fernandez-Ruiz J., García C., Sagredo O., Gómez-Ruiz M., de Lago E. The endocannabinoid system as a target for the treatment of neuronal damage. Expert Opin. Ther. Targets 2010, 4:387-404.
31. Hanisch U.K., Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat. Neurosci. 2007, 10:1387-1394.
32. Jankovic D., Trinchieri G. IL-10 or not IL-10: that is the question. Nat. Immunol. 2007, 8:1281-1283.
33. Johnson R.T. The virology of demyelinating diseases. Ann. Neurol. 1994, 36(Suppl.):S54-S60.
34. Kastelein R.A., Hunter C.A., Cua D.J. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu. Rev. Immunol. 2007, 25:221-242.
35. Lambert D.M., Fowler C.J. The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J. Med. Chem. 2005, 48:5059-5087.
36. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., McClanahan T., Kastelein R.A., Cua D.J. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 2005, 201:233-240.
37. Li Y., Chu N., Hu A., Gran B., Rostami A., Zhang G.X. Increased IL-23p19 expression in multiple sclerosis lesions and its induction in microglia. Brain 2007, 130:490-501.
38. Liu Y.W., Chen C.C., Tseng H.P., Chang W.C. Lipopolysaccharide-induced transcriptional activation of interleukin-10 is mediated by MAPK and NFkappaB-induced CCAAT/enhancer-binding protein delta in mouse macrophages. Cell Signal. 2006, 18:1492-1500.
39. Loría F., Petrosino S., Mestre L., Spagnolo A., Correa F., Hernangómez M., Guaza C., Di Marzo V., Docagne F. Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. Eur. J. Neurosci. 2008, 28:633-641.
40. Loría F., Petrosino S., Hernangómez M., Mestre L., Spagnolo A., Correa F., Di Marzo V., Docagne F., Guaza C. An endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosis. Neurobiol. Dis. 2010, 37:166-176.
41. Mack C.L., Vanderlugt-Castaneda C.L., Neville K.L., Miller S.D. Microglia are activated to become competent antigen presenting and effector cells in the inflammatory environment of the Theiler's virus model of multiple sclerosis. J. Neuroimmunol. 2003, 144:68-79.
42. Matias I., Pochard P., Orlando P., Salzet M., Pestel J., Di Marzo V. Presence and regulation of the endocannabinoid system in human dendritic cells. Eur. J. Biochem. 2002, 269:3771-3778.
43. Mc Mahon E.J., Bailey S.L., Vanderlugt Castenada C., Waldner H., Miller S.D. Epitope spreading initialtes in the CNS in two mouse models of multiple sclerosis. Nat. Med. 2005, 11:335-339.
44. McGavern D.B., Murray P.D., Rivera-Quinones C., Schmelzer J.D., Low P.A., Rodriguez M. Axonal loss results in spinal cord atrophy, electrophysiological abnormalities and neurological deficits following demyelination in a chronic inflammatory model of multiple sclerosis. Brain 2000, 123:519-531.
45. Mestre L., Correa F., Arévalo-Martín A., Molina-Holgado E., Valenti M., Ortar G.M., Di Marzo V., Guaza C. Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. J. Neurochem. 2005, 92:1327-1339.
46. Molina-Holgado E., Vela J.M., Arévalo-Martín A., Guaza C. LPS/IFN-gamma mediated citotoxicity in oligodendroglial cells: Role of NO and protection by the anti-inflammatory cytokine IL-10. Eur. J. Neurosci. 2001, 13:493-502.
47. Molina-Holgado E., Arévalo-Martín A., Castrillo A., Bosca L., Vela J.M., Guaza C. Interleukin-4 and interleukin-10 modulate nuclear factor kappaB activity and nitric oxide synthase-2 expression in Theiler's virus-infected brain astrocytes. J. Neurochem. 2002, 81:1242-1252.
48. Murphy C.A., Langrish C.L., Chen Y., Blumenschein W., McClanahan T., Kastelein R.A., Sedgwick J.D., Cua D.J. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med. 2003, 198:1951-1957.
49. Nakahara T., Uchi H., Urabe K., Chen Q., Furue M., Moroi Y. Role of c-Jun N-terminal kinase on lipopolysaccharide induced maturation of human monocyte-derived dendritic cells. Int. Immunol. 2004, 16:1701-1709.
50. Noseworthy J.H., Lucchinetti C., Rodríguez M., Weinshenker B.G. Multiple sclerosis. N. Engl. J. Med. 2000, 343:938-952.
51. O'Garra A., Barrat F.J., Castro A.G., Vicari A., Hawrylowicz C. Strategies for use of IL-10 or its antagonists in human disease. Immunol. Rev. 2008, 223:114-131.
52. Olson J.K., Miller S.D. Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J. Immunol. 2004, 173:3916-3924.
53. Oppmann B., Lesley R., Blom B., Timans J.C., Xu Y., Hunte B., Vega F., Yu N., Wang J., Singh K., Zonin F., Vaisberg E., Churakova T., Liu M., Gorman D., Wagner J., Zurawski S., Liu Y., Abrams J.S., Moore K.W., Rennick D., de Waal-Malefyt R., Hannum C., Bazan J.F., Kastelein R.A. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000, 13:715-725.
54. Ortega-Gutiérrez S., Molina-Holgado E., Arévalo-Martín A., Correa F., Viso A., López-Rodriguez M.L., Di Marzo V., Guaza C. Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis. FASEB J. 2005, 19:1338-1345.
55. Pena-Rossi C., Delcroix M., Huitinga I., McAllister A., van Claassen R.N., Brahic M. Role of macrophages during Theiler's virus infection. J. Virol. 1997, 71:3336-3341.
56. Romero J., Orgado J.M. Cannabinoids and neurodegenerative diseases. CNS Neurol. Disord. Drug Targets 2009, 8:440-450.
57. Saegusa K., Yotsumoto S., Kato S., Aramaki Y. Phosphatidylinositol 3-kinase-mediated regulation of IL-10 and IL-12 production in macrophages stimulated with CpG oligodeoxynucleotide. Mol. Immunol. 2007, 44:1323-1330.
58. Segal B.M., Dwyer B.K., Shevach E.M. An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J. Exp. Med. 1998, 187:537-546.
59. Stella N. Cannabinoid signaling in microglial cells. Neuropharmacology 2009, 56:244-253.
60. Stritesky G.L., Yeh N., Kaplan M.H. IL-23 promotes maintenance but not commitment to the Th17 lineage. J. Immunol. 2008, 181:5948-5955.
61. Tomczak M.F., Gadjeva M., Wang Y.Y., Brown K., Maroulakou I., Tsichlis P.N., Erdman S.E., Fox J.G., Horwitz B.H. Defective activation of ERK in macrophages lacking the p50/p105 subunit of NF-kappaB is responsible for elevated expression of IL-12 p40 observed after challenge with Helicobacter hepaticus. J. Immunol. 2006, 176:1244-1251.
62. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 2003, 3:133-146.
63. Utsugi M., Dobashi K., Ishizuka T., Endou K., Hamuro J., Murata Y., Nakazawa T., Mori M. C-Jun N-terminal kinase negatively regulates lipopolysaccharide-induced IL-12 production in human macrophages: role of mitogen-activated protein kinase in glutathione redox regulation of IL-12 production. J. Immunol. 2003, 171:628-635.
64. Walter L., Franklin A., Witting A., Wade C., Xie Y., Kunos G., Stella N. Non-psychotropic cannabinoid receptors regulate microglia cell migration. J. Neurosci. 2003, 23:1398-1405.
65. Windhagen A., Newcombe J., Dangond F., Strand C., Woodroofe M.N., Cuzner M.L., Hafler D.A. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J. Exp. Med. 1995, 182:1985-1996.
66. Wolf S.A., Ullrich O. Endocannabinoids and the brain immune system: new neurons at the horizon?. J. Neuroendocrinol. 2008, 20:15-19.
67. Xin, J., Wainwright, D.A., Mesnard, N.A., Serpe, C.J., Sanders, V.M., Jones, K.J. 2010. IL-10 within the CNS is necessary for CD4+ T cells to mediate neuroprotection. Brain Behav. Immun. in press, doi:10.1016/j.bbi.2010.08.004.
68. Yen D., Cheung J., Scheerens H., Poulet F., McClanahan T., McKenzie B., Kleinschek M.A., Owyang A., Mattson J., Blumenschein W., Murphy E., Sathe M., Cua D.J., Kastelein R.A., Rennick D. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin. Invest. 2006, 116:1310-1316.
69. Zheng L., Calenoff M.A., Dal Canto M.C. Astrocytes, not microglia, are the main cells responsible for viral persistence in Theiler's murine encephalomyelitis virus infection leading to demyelination. J. Neuroimmunol. 2001, 118:256-262.
70. Zhou P., Streutker C., Borojevic R., Wang Y., Croitoru A. IL-10 modulates intestinal damage and epithelial cell apoptosis in T cell-mediated enteropathy. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 287:G599-G604.